You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 46 No. 6, June 1989 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on Web of Science (20)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Neuroendocrine Responses to Physostigmine in Alzheimer's Disease

Murray A. Raskind, MD; Elaine R. Peskind, MD; Richard C. Veith, MD; Steven C. Risse, MD; Thomas H. Lampe, MD; Soo Borson, MD; Gail Gumbrecht; Daniel M. Dorsa, PhD

Arch Gen Psychiatry. 1989;46(6):535-540.


Abstract

• To assess central nervous system cholinergic neuroendocrine regulation in Alzheimer's disease (AD), we measured plasma arginine vasopressin, β-endorphin, and epinephrine responses to a cholinergic challenge elicited by intravenous administration of the acetylcholinesterase inhibitor physostigmine (0.0125 mg/kg) in male patients with AD (n =12) and compared their responses with those of age-matched normal control subjects (n =12). Physostigmine promptly increased plasma arginine vasopressin (tenfold), β-endorphin (twofold to threefold) and epinephrine (threefold) levels in elderly control subjects. In contrast, patients with AD showed attenuated responses to physostigmine. When controls and patients with AD who experienced nausea (n = 2 and n = 6, respectively) were excluded, the arginine vasopressin, β-endorphin, and epinephrine responses of patients with AD were significantly less than those of control subjects. These data suggest that the central nervous system cholinergic deterioration of AD results in decreased responsiveness of neuroendocrine systems that are regulated by central cholinergic mechanisms.



Author Affiliations

From the Departments of Psychiatry and Behavioral Sciences (Drs Raskind, Peskind, Veith, Risse, Lampe, Borson, and Dorsa and Ms Gumbrecht), Medicine (Dr Dorsa), and Pharmacology (Dr Dorsa), University of Washington School of Medicine, Seattle; and the Seattle-American Lake Veterans Administration Geriatric Research, Education, and Clinical Center (Drs Raskind, Peskind, Veith, Risse, Lampe, Borson, and Dorsa and Ms Gumbrecht).


Footnotes

Accepted for publication Aug 5, 1988.

Reprint requests to Geriatric Research, Education and Clinical Center, Veterans Administration Medical Center, 1660 S Columbian Way, Seattle, WA 98108 (Dr Raskind).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1989 American Medical Association. All Rights Reserved.